US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.89 ▼-1.02% TSLA $378.69 ▲+2.18% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

29.67 +0.67 (+2.31%)
Official Closing Price Updated: 4:10 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
61 62 Next >
News headline image
1 Small-Cap Stock with Exciting Potential and 2 We Avoid
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
MarketBeat Week in Review – 11/17 - 11/21 ↗
Via MarketBeat
News headline image
2 Cash-Heavy Stocks with Competitive Advantages and 1 We Find Risky
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
News headline image
KeyCorp Delivers Sobering Outlook for LifeMD, Slashing Price Target Amidst Operational Headwinds
KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a... 
Via MarketMinute
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗
Via Stocktwits
News headline image
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗
Via MarketBeat
News headline image
Ready For A Rebound? Here Are 10 Oversold Stocks To Watch ↗
Many popular stocks have been beaten down to attractive levels, creating potential opportunities for those eyeing a rebound. 
Via Benzinga
News headline image
Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4.9% in the afternoon session after news of increased competition in the weight-loss drug market overshadowed the company’s own positive... 
Via StockStory
News headline image
What's Going On With Hims & Hers Health Shares Monday? ↗
Shares of Hims & Hers are trading marginally lower Monday morning, as competitive news overshadows bullish announcements from the company. 
Via Benzinga
News headline image
Hims & Hers Announces New $250 Million Share Repurchase Program – Retail Sees A Steady Trading Range For The Stock ↗
The latest buyback program follows a $100 million share buyback program in July 2024, which has now been completed. 
Via Stocktwits
News headline image
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
From Hims & Hers
Via Business Wire
News headline image
Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy
From Hims & Hers
Via Business Wire
News headline image
Hims & Hers Introduces Labs With Annual Plans For Comprehensive Testing ↗
Hims & Hers launches Labs, offering annual biomarker testing plans with doctor-developed guidance and expanded diagnostics planned across key health categories. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and... 
Via StockStory
Topics Stocks
News headline image
Hims & Hers Stock Logs 3-Day Losing Streak As Truist Calls Out Klarna GLP-1 Changes — Retail Sees Fresh Buy Zone ↗
Truist pointed to updated GLP-1 intake features, including Klarna financing, shorter shipping intervals and new semaglutide microdosing options. 
Via Stocktwits
News headline image
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks ↗
Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten. 
Via Benzinga
News headline image
Hims & Hers Introduces Labs, a Holistic, In-Depth Testing Experience That Puts Customers in Control of Their Health and Wellness Journeys
From Hims & Hers
Via Business Wire
News headline image
2 Strong Healthcare Stock Picks for Growth Investors ↗
If you're a growth-oriented stock buyer, there are plenty of options in the healthcare space. 
Via The Motley Fool
News headline image
2 Quality Healthcare Stocks That Could Build a Strong Foundation for Beginner Investors ↗
Healthcare stocks have plenty to offer new investors. 
Via The Motley Fool
News headline image
Huge Opportunity to Buy These 4 Stocks ↗
All four of these stocks have big upside. 
Via The Motley Fool
News headline image
Healthcare Technology Stocks Q3 Teardown: Hims & Hers Health (NYSE:HIMS) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how healthcare technology stocks fared in Q3, starting with Hims... 
Via StockStory
News headline image
Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants ↗
Although Hims & Hers Health has tanked in the past month, the quantitative profile suggests a contrarian trade is brewing for HIMS stock. 
Via Benzinga
News headline image
Hims & Hers Health’s Q3 Earnings Call: Our Top 5 Analyst Questions
Hims & Hers Health’s third quarter results prompted a positive market reaction as the company delivered strong revenue growth driven by surging demand for personalized care, new specialty launches, and... 
Via StockStory
Topics Earnings
News headline image
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? ↗
The company continues to have a strong growth outlook ahead. 
Via The Motley Fool
News headline image
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned. 
Via Investor's Business Daily
Topics Government
News headline image
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced ↗
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage. 
Via Stocktwits
Topics Government World Trade
News headline image
1 Growth Stock to Stash and 2 We Ignore
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
News headline image
Why Are Hims & Hers Health (HIMS) Shares Soaring Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 6.9% in the morning session after the company reported third-quarter 2025 results that showed strong revenue growth, even as its... 
Via StockStory
News headline image
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results ↗
Via MarketBeat
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
61 62 Next >